1. Home
  2. VYGR vs MTA Comparison

VYGR vs MTA Comparison

Compare VYGR & MTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • MTA
  • Stock Information
  • Founded
  • VYGR 2013
  • MTA 1983
  • Country
  • VYGR United States
  • MTA Canada
  • Employees
  • VYGR N/A
  • MTA N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • MTA
  • Sector
  • VYGR Health Care
  • MTA
  • Exchange
  • VYGR Nasdaq
  • MTA Nasdaq
  • Market Cap
  • VYGR 222.9M
  • MTA 267.2M
  • IPO Year
  • VYGR 2015
  • MTA N/A
  • Fundamental
  • Price
  • VYGR $3.16
  • MTA $3.14
  • Analyst Decision
  • VYGR Strong Buy
  • MTA Hold
  • Analyst Count
  • VYGR 9
  • MTA 1
  • Target Price
  • VYGR $14.86
  • MTA $4.50
  • AVG Volume (30 Days)
  • VYGR 396.9K
  • MTA 413.8K
  • Earning Date
  • VYGR 05-12-2025
  • MTA 05-14-2025
  • Dividend Yield
  • VYGR N/A
  • MTA N/A
  • EPS Growth
  • VYGR N/A
  • MTA N/A
  • EPS
  • VYGR N/A
  • MTA N/A
  • Revenue
  • VYGR $80,001,000.00
  • MTA $5,882,000.00
  • Revenue This Year
  • VYGR N/A
  • MTA $137.30
  • Revenue Next Year
  • VYGR $2.04
  • MTA $45.61
  • P/E Ratio
  • VYGR N/A
  • MTA N/A
  • Revenue Growth
  • VYGR N/A
  • MTA 28.01
  • 52 Week Low
  • VYGR $2.75
  • MTA $2.32
  • 52 Week High
  • VYGR $9.55
  • MTA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 38.34
  • MTA 59.85
  • Support Level
  • VYGR $2.75
  • MTA $2.53
  • Resistance Level
  • VYGR $3.34
  • MTA $3.23
  • Average True Range (ATR)
  • VYGR 0.26
  • MTA 0.16
  • MACD
  • VYGR 0.03
  • MTA 0.04
  • Stochastic Oscillator
  • VYGR 41.41
  • MTA 87.14

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.

Share on Social Networks: